Alnylam Pharmaceuticals Inc
Research Alnylam Pharmaceuticals Inc (ALNY) on Bullrun: market cap USD 31.12B, P/E 39.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALNY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 31.12B
- P/E39.3
- Financial periodQ2 2026
- RevenueUSD 1.29B
- Net incomeUSD 164.49M
- Free cash flowUSD 292.04M
- Gross margin76.9%
Valuation Snapshot
latest market cap is USD 31.12B; P/E is 39.3.
Peer valuation comparison
Latest P/E is 39.28x versus a Healthcare sector median of 24.61x (59.6% above).
Latest P/E is 39.28x versus a United States median of 23.85x (64.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.71B | USD 313.75M | USD 465.38M | 81.8% | 2.33 | USD 1.66B | USD 1.28B | USD 789.18M |
| FY2024 | USD 2.25B | -USD 278.16M | -USD 42.59M | 86.4% | -2.18 | USD 966.43M | USD 1.30B | USD 67.09M |
| FY2023 | USD 1.83B | -USD 440.24M | USD 41.95M | 85.3% | -3.52 | USD 812.69M | USD 1.31B | -USD 220.64M |
| FY2022 | USD 1.04B | -USD 1.13B | -USD 613.33M | 86.5% | -9.3 | USD 866.39M | USD 1.32B | -USD 158.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 31.12B | 39.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 52.64B | 176.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 30.42B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 24.02B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 29.24B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 20.38B | n/a | n/a | n/a |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
ETFs that hold Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc is one of the ten largest holdings of 3 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | 2.81% | 0.35% |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 2.16% | 0.35% |
| VanEck Genomics and Healthcare Innovators UCITS ETF | 3.43% | 0.35% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alnylam Pharmaceuticals Inc's market cap?
Alnylam Pharmaceuticals Inc's market capitalization is USD 31.12B.
What is Alnylam Pharmaceuticals Inc's P/E ratio?
Alnylam Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 39.3.
What does Alnylam Pharmaceuticals Inc do?
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.